Captopril

CHEMBL1560 Phase 4 Aprobado Small molecule
Half-Life
1.9 hours
Bioavailability
Protein Binding
Molecular Weight
217.3 g/mol
LogP
0.3
Phase
4

The first orally active ACE inhibitor, used to treat hypertension, heart failure, and to protect kidney function in diabetic nephropathy. By blocking the angiotensin-converting enzyme, it prevents the formation of angiotensin II, leading to blood vessel relaxation and reduced aldosterone secretion. A dry persistent cough is a characteristic and common side effect.

Peso molecular

217,2850 g/mol

LogP

0,30

TPSA

58,60 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Clases de fármacos

Mecanismo de acción

First orally active ACE inhibitor; contains thiol group that binds zinc at ACE active site.

Pharmacokinetics (PK)

Half-Life 1.9 hours

Pharmacodynamics (PD)

Mecanismo

First orally active ACE inhibitor; contains thiol group that binds zinc at ACE active site.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O

InChI

InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1

Molecular Formula

C9H15NO3S

HBD / HBA

2 / 4

Enlaces Rotables

3

Átomos Pesados

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

The first orally active ACE inhibitor, used to treat hypertension, heart failure, and to protect kidney function in diabetic nephropathy. By blocking the angiotensin-converting enzyme, it prevents the formation of angiotensin II, leading to blood vessel relaxation and reduced aldosterone secretion. A dry persistent cough is a characteristic and common side effect.

First orally active ACE inhibitor; contains thiol group that binds zinc at ACE active site.

Key pharmacokinetic parameters for Captopril: Half-life: 1.9 hours.

Yes, Captopril is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1560. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 44093. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.